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Genomics-driven discovery of a novel glutarimide antibiotic from 
Burkholderia gladioli reveals an unusual polyketide synthase 
chain release mechanism 
Ioanna T. Nakou,[a]† Matthew Jenner,[a,b]† Yousef Dashti,[a]†‡ Isolda Romero-Canelón,[c] Joleen 
Masschelein,[a]‡ Eshwar Mahenthiralingam[d] and Gregory L. Challis[a,b,e]*
[a] I.T. Nakou, Dr. M. Jenner, Dr. Y. Dashti, Prof. J. Masschelein 
Prof. G. L. Challis  
Department of Chemistry, University of Warwick 
Coventry CV4 7AL (United Kingdom). 
E-mail: g.l.challis@warwick.ac.uk
[b] Dr. M. Jenner, Prof. G. L. Challis. 
Warwick Integrative Synthetic Biology Centre 
University of Warwick 
Coventry CV4 7AL (United Kingdom). 
[c] Dr. I. Romero-Canelón 
Institute of Clinical Sciences 
School of Pharmacy 
University of Birmingham,  
Birmingham B15 2TT (United Kingdom) 
[d] Prof. E. Mahenthiralingam 
Organisms and Environment Division 
Cardiff School of Biosciences 
Cardiff University 
Cardiff CF10 3AT (United Kingdom) 
Abstract: A gene cluster encoding a cryptic trans-acyl transferase 
polyketide synthase (PKS) was identified in the genomes of 
Burkholderia gladioli BCC0238 and BCC1622, both isolated from the 
lungs of cystic fibrosis patients. Bioinfomatics analyses indicated the 
PKS assembles a novel member of the glutarimide class of antibiotics, 
hitherto only isolated from Streptomyces species. Screening of a 
range of growth parameters enabled gladiostatin, the metabolic 
product of the PKS, to be identified. NMR spectroscopic analysis 
revealed that gladiostatin, which has promising activity against 
several human cancer cell lines and inhibits tumor cell migration, 
contains an unusual 2-acyl-4-hydroxy-3-methylbutenolide in addition 
to the glutarimide pharmacophore. An AfsA-like domain at the C-
terminus of the PKS was shown to catalyze condensation of 3-
ketothioesters with dihydroxyacetone phosphate, indicating it plays a 
key role in polyketide chain release and butenolide formation. 
Introduction 
The constant competition between microbes and their 
environment has driven the evolution of specialised metabolite 
production in bacteria, enabling rapid ecological adaptation.[1]
Such metabolites frequently find important applications in 
medicine, as antibiotics, anticancer agents and immune 
modulators, and agriculture, as insecticides, herbicides and 
fungicides. Gram-negative bacteria belonging to the Burkholderia
genus produce a wide array of bioactive specialised metabolites, 
including the respiratory toxin bongkrekic acid, anti-proliferative 
agents such as thailanstatin and spliceostatin, and the antibiotics 
enacyloxin IIa and gladiolin.[2–5] Despite their structural complexity 
and diversity, these molecules are biosynthesised from simple 
building blocks by modular polyketide synthase (PKS) and non-
ribosomal peptide synthetase (NRPS) assembly lines, often 
harbouring non-canonical characteristics.[6,7] Recently, we have 
shown that the opportunistic pathogen Burkholderia gladioli
BCC0238, isolated from the lung of a cystic fibrosis (CF) patient, 
produces a range of specialised metabolites, dependent on the 
carbon source. When glycerol is used as the carbon source, this 
strain produces gladiolin, a novel macrolide with promising activity 
against Mycobacterium tuberculosis, and the swarming inhibitor 
icosalide A1, which was originally isolated from a filamentous 
fungus, but has subsequently been shown to originate from a 
Burkholderia symbiont.[8–10] Switching to a mixture of glycerol and 
ribose as carbon sources, induces the production of bolagladins 
A and B, novel lipodepsipeptides containing a unique citrate-
primed fatty acid and an unusual dehydro-β-alanine residue.[11]
Although several specialised metabolites and their 
associated biosynthetic gene clusters (BGCs) have already been 
identified in B. gladioli BCC0238, analysis of the complete 
genome sequence of this strain indicated that it contains 
numerous cryptic BGCs, the metabolic products of which are 
currently unknown.8 Here we report the discovery of gladiostatin, 
a novel member of the glutarimide class of polyketide antibiotics, 
as the metabolic product of a cryptic trans-AT PKS-encoding BGC 
in B. gladioli BCC0238. This unusual metabolite, which contains 
a rare 2-acyl-3-methyl-4-hydroxybutenolide in addition to the 2, 6-
piperidinedione common to all glutarimides, is active against 
yeast and has promising activity against several human cancer  
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Fig. 1. Comparison of Streptomyces glutarimide biosynthetic gene clusters and polyketide synthases they encode with that encoded by the cryptic B. 
gladioli gene cluster and role played by phosphorylated butenolide synthases in Streptomyces signalling molecule biosynthesis. a) Comparison of 
biosynthetic gene clusters (BGCs) that direct glutarimide biosynthesis in Streptomyces species (9-methylstreptimidone (smd), cycloheximide (chx), lactimidomycin 
(ltm) and migrastatin (mgs)) with the cryptic B. gladioli BCC0238/BCC1622 gene cluster (highlighted by the red box). The genes (or regions thereof) encoding the 
machinery responsible for assembling the common 2-(2,6-dioxopiperidin-4-yl)acetyl thioester biosynthetic intermediate are highlighted in gold. b) Comparison of 
the 9-methylstreptimidone, cycloheximide, lactimidomycin and migrastatin PKS architectures with the PKS encoded by the cryptic B. gladioli BGC. Domains 
highlighted in dark yellow are involved in constructing the common 2-(2,6-dioxopiperidin-4-yl)acetyl thioester intermediate. Domains responsible for chain release 
(TE and PBS) are highlighted in green. Abbreviations for protein domains are displayed in the dashed box. c) Structures of glutarimide antibiotics produced by 
Streptomyces species. d) Structures of Streptomyces signalling molecules known or proposed to originate from a phosphorylated butenolide intermediate resulting 
from PBS-catalysed condensation of DHAP with a 3-ketoacyl-ACP/CoA thioester. 
cell lines. Gene disruption experiments confirmed that the BGC 
directs the biosynthesis of gladiostatin, and chain release from the 
PKS was reconstituted in vitro, providing insights into the 
mechanism for formation of the unusual butenolide moiety. These 
experiments enabled us to propose a biosynthetic pathway for 
gladiostatin, the first glutarimide to be isolated from Gram-
negative bacteria, illuminating the role played by horizontal gene 
transfer in trans-AT PKS evolution. 
Results and Discussion 
Genome mining identifies a cryptic trans-AT PKS predicted 
to assemble a novel glutarimide 
Building on our previous work in B. gladioli BCC0238, in silico
analysis of the genome sequence revealed a ~50 kb cryptic BGC 
encoding a trans-AT PKS on the second chromosomal replicon 
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proteins encoded by this BGC are very similar to enzymes known 
to be involved in the biosynthesis of the glutarimide class of 
polyketide 
antibiotics in Streptomyces species (Fig. 1a and 1b), including 
cycloheximide (1),[12,13] 9-methylstreptimidone (2),[14,15]
migrastatin/iso-migrastatin (3)[16–18] and lactimidomycin (4).[19,20]
Glutarimides have potent antifungal activity and inhibit eukaryotic 
translation by blocking the binding of tRNA to the E-site of the 60S 
ribosomal subunit.[21,22] They also possess promising anticancer 
activity and several members of the family have been reported to 
inhibit tumour cell-migration (Fig. 1c, Fig. S2).[23,24]
Three conserved genes (smdFGH, chxBCD, ltmHCD and
mgsHCD in the 9-methylstreptimidone, cycloheximide, 
lactimidomycin and migrastatin BGCs, respectively) encode 
proteins that are proposed to create a common malonamyl 
thioester starter unit for the PKSs that assembles these 
metabolites  (Fig. 1a).[12,15–20] These genes encode: an 
acyltransferase (AT; SmdF/ChxB/LtmH/MgsH) that is proposed to 
malonylate an acyl carrier protein (ACP; 
SmdG/ChxC/LtmC/MgsC); and an asparagine synthetase 
homologue (SmdH/ChxD/LtmD/MgsD), which is hypothesised to 
convert the resulting malonyl thioester to a malonamyl thioester. 
The first module in each PKS (located in the SmdI, ChxE, LtmE 
and MgsE subunits) contains seven conserved domains that are 
proposed to elaborate the malonamyl starter unit into a common 
2-(2,6-dioxopiperidin-4-yl)acetyl thioester intermediate (Fig. 
1b).[25]
Fig. 2. Identification and structure elucidation of metabolic products of the 
cryptic trans-AT PKS in B. gladioli BCC1622. a). Structure elucidation of 
degradation product (5) (top) and gladiostatin (6) (bottom). COSY and key 
HMBC correlations observed for each compound are indicated by bold lines and 
arrows, respectively. b). Extracted ion chromatograms at m/z = 506.27 ± 0.02, 
(corresponding to the [M+H]+ ion of gladiostatin) from UHPLC-ESI-Q-TOF-MS 
analysis of ethyl actetate extracts from B. gladioli BCC1622 grown on a minimal 
medium containing different carbon sources.
The gdsB, gdsC and gdsD genes in the cryptic B. gladioli
BGC encode homologues of the three proteins hypothesised to 
create the malonamyl thioester starter unit (Fig. 1b). Moreover, 
the first module of the PKS encoded by this cluster (situated in the 
GdsE subunit) has an identical seven-domain architecture to the 
corresponding modules of the PKSs that assemble the 
Streptomyces glutarimides. However, the domain architecture of 
subsequent modules in the B. gladioli PKS differs significantly 
from the Streptomyces glutarimide assembly lines and a unique 
AfsA-like domain (pfam03756 – identified by a conserved domain 
search) is appended to the C-terminus of the final PKS module 
(Fig. 1b). AfsA catalyses the condensation of dihydroxyacetone 
phosphate (DHAP) with a β-keto thioester to form a 
phosphorylated butenolide intermediate in the biosynthesis of A-
factor, a signalling molecule that controls morphological 
differentiation and antibiotic production in Streptomyces griseus 
(Fig. 1d).[26] AfsA homologues are proposed to catalyse 
analogous reactions in the biosynthesis of other γ-butyrolactones 
(GBLs), such as the Streptomyces coelicolor butyrolactones and 
the Streptomyces virginiae butanolides (Fig. 1d).[27,28] Members 
of this enzyme family are also involved in the biosynthesis of other 
classes of Streptomyces signalling molecules, such as 2-alkyl-4-
hydroxymethylfuran-3-carboxylic acids (AHFCAs), typified by the 
meythylenomycin furans, and 2-alkyl-4-hydroxy-3-
methlylbutenolides (AHMBs), exemplified by the Streptomyces 
rochei butenolides and the Streptomyces ansachromogenes
butenolides (Fig. 1d).[29–31] Incorporation experiments with 
stereospecifically 13C-labelled glycerols indicate that an 
analogous phosphorylated butenolide to that formed by AfsA in A-
factor biosynthesis is an intermediate in the biosynthesis of the 
methylenomycin furans.[32] This suggests that the AfsA family of 
enzymes involved in GBL, AHFCA and AHMB assembly all 
produce analogous phosphorylated butenolides that are 
diversified by subsequent biosynthetic enzymes (Fig. 1d).
PKSs typically have a thioesterase (TE) domain appended 
to the C-terminus of the last module, which catalyses release of 
the fully assembled polyketide chain via hydrolysis or 
macrocyclisation, but several other chain release mechanisms 
are known.[33–36] Based on the role played by AfsA family enzymes 
in Streptomyces signalling molecule biosynthesis, we 
hypothesised that the AfsA-like domain appended to the C-
terminus of the last module in the cryptic B. gladioli PKS releases 
the fully assembled polyketide chain by condensing it with DHAP 
to form a phosphorylated butenolide (Fig. 1d). Accordingly, we 
designated this new type of chain release enzyme as a 
phosphorylated butenolide synthase (PBS) domain. Overall, our 
in silico analyses indicated that the cryptic B. gladioli PKS 
assembles a novel glutarimide-containing polyketide with 
significant structural differences to the glutarimide antibiotics 
assembled by Streptomyces species. 
Isolation and structure elucidation of metabolic products of 
the cryptic PKS 
We originally identified the BGC encoding the cryptic trans-
AT PKS in B. gladioli BCC0238. However, due to difficulties with 
creating in-frame deletions in this strain, we searched the 
genomes of other B. gladioli strains to see if they contain this BGC. 
Another CF isolate, B. gladioli BCC1622, which is more amenable 
to genetic manipulation,[11] was also found to contain the cluster. 
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UHPLC-ESI-Q-TOF-MS analysis of an ethyl acetate extract from 
a culture of B. gladioli BCC1622, grown for 3 days on a minimal
agar medium containing glycerol as the sole carbon source, 
identified a metabolite with the molecular formula C23H37NO5 (Fig. 
S3) . 
The planar structure of this metabolite (5) was elucidated 
using 1H, 13C, COSY, HSQC and HMBC NMR experiments (Fig. 
2a, Fig. S4-S8, Table S1). HMBC correlations between H-3 and 
C-1 / C-1’ and the exchangeable NH proton and C-2 / C-2’ 
confirmed the presence of a 2, 6-piperidinedione, and the 
chemical shift values for this moiety were in good agreement with 
the literature.[18,19,37,38] Two networks of COSY correlations 
established the structures of the C-2 / C-2’ to C-6 and C-8 to C-
18 regions of the molecule, and HMBC correlations further 
confirmed the locations of the C-8 Me group and the C-9/C-10 
double bond. HMBC correlations also showed that C-6 and C-8 
are connected via a keto group and that a methyl ketone is 
attached to C-18. Based on a 3JHH coupling constant of 15 Hz, the 
C-9/C-10 double bond was assigned the E configuration. 
Although compound 5 contains the anticipated 2, 6-
piperidinedione, it lacks the butenolide predicted to be installed by 
the PBS domain (Fig. 1d). We thus postulated that this compound 
results from degradation of the true metabolic product of the BGC. 
A range of carbon sources (glycerol, glucose, ribose) and growth 
periods were explored to investigate whether other metabolic 
products of the BGC could be identified. UHPLC-ESI-Q-TOF-MS 
analysis of an ethyl acetate extract from a 24 hour culture on a 
minimal medium containing glucose as the sole carbon source 
identified a new metabolite with the molecular formula C27H39NO8
(Fig. 2b and Fig. S9). A time course showed that production of 
this metabolite peaked at 20 hours and fell off rapidly over more 
protracted growth periods (Fig. S10). After 55 hours, small 
amounts of compound 5 could be detected, consistent with this 
being a degradation product of the new metabolite.    
Comparison of the molecular formulae for compound 5 and 
the newly identified metabolite showed the latter contains four 
additional carbon atoms, and three additional hydrogen and 
oxygen atoms. The planar structure of the new metabolite (6) was 
elucidated using 1H, 13C, COSY, HSQC and HMBC NMR 
experiments (Fig. 2a, Fig. S11-S15, Table S2). The 13C NMR 
spectrum of 6 lacked the signal due to methyl ketone in 5 and 
contained additional signals assigned to a carbonyl group (C-21), 
two fully substituted alkene carbons (C-20 and C-2’’), a methyl 
group (C-3’’) and a hemiacetal (C-1’’). HMBC correlations 
between the C-3’’ protons and C-1’’ / C-20 and the C-1’’ proton 
and C-2’’ / C-21 led us to propose that this molecule contains a 2-
subsituted 4-hydroxy-3-methylbutenolide. The NMR data for this 
moiety are similar to those reported for the AHMBs isolated from 
S. rochei and S. ansachromogenes (Fig. 1d).[30,31] An HMBC 
correlation between the C-18 protons and C-20 established the 
connectivity between the butenolide and the rest of the structure. 
The juxtaposition of a 2-acyl-4-hydroxy-3-methylbutenolide and 2, 
6-piperidinedione in this molecule, coupled with the time course 
data for its production, led us to conclude that this compound, 
which we named gladiostatin, is the true metabolic product of the 
cryptic glutarimide-like BGC in B. gladioli BCC1622 and BCC0238. 
Gladiostatin (6) is likely degraded to 5 via conjugate addition of 
water to the butenolide, followed by ring opening, decarboxylation 
and retro-Aldol cleavage (Fig. S16).   




Klebsiella pneumonia DSM 26371 >64 
Acinetobacter baumannii DSM25645 >64 
Pseudomonas aeruginosa DSM29239 >64 
Enterobacter cloacae DSM 16690 >64 
Gram-positive Bacteria 
Enterococcus faecium DSM25390 >64 
Staphylococcus aureus DSM21979 >64 
Fungi 
Candida albicans SC 5314 >64 
Yeast 
S. cerevisiae W303-1a 4 
Table 2. Anticancer activity of gladiostatin. 
gladiostatin (6) 
Cancer cell line  IC50 (μΜ) 
A2780 (ovarian) 0.24 ± 0.03 
A549 (lung) no activity 
MiaPaca2 (pancreatic) 0.57 ± 0.06 
HCTT116 P53 -/- (colon) 0.82 ± 0.04 
SKOV3 (ovarian) 0.6 ± 0.1 
PEA1 (ovarian) 1.4 ± 0.1 
Fig. 3. Inhibition of A2780 ovarian tumour cell migration by gladiostatin.
The bar chart shows wound-width values after 24 hrs ± treatment with 240 nM 
gladiostatin (6).  
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Biological activity of gladiostatin 
Initially, we tested the activity of gladiostatin (6) against 
representative members of the ESKAPE panel of bacterial 
pathogens, Candida albicans and Saccharomyces cerevisiae. 
While no activity was detected against the bacterial pathogens or 
C. albicans at concentrations up to 64 μg/ml, it was found to be 
active against S. cerevisiae, with an MIC of 4 μg/ml (Table 1). 
Prompted by reports that several glutarimides have anti-
tumour activity,[23,24] we investigated the activity of gladiostatin (6) 
against a range of cancer cell lines (Table 2). It was found to be 
active against ovarian, pancreatic and colon  cancer cell lines 
(Table 2). These values are in the same range as those reported 
for cycloheximide (1), migrastatin (3) and lactimidomycin (4) 
against various other cell lines (Table S6).[17,19,38] Interestingly, 
gladiostatin (6) was found to be inactive against the A549 lung 
cancer cell line, indicating it may exhibit some selectivity.  
Some glutarimides have also been reported to inhibit 
tumour cell migration.[23,24] Thus, we used a wound-healing assay 
to test whether gladiostatin (6) can inhibit the migration of A2780 
ovarian cancer cells. Strong suppression of cell migration was 
observed after 24h exposure to 240 nM gladiostatin (Fig. 3, Fig. 
S17).
Proposed pathway for gladiostatin biosynthesis. 
To establish that the gds cluster directs the biosynthesis of 
gladiostatin (6), gdsE, which encodes the first polyketide synthase 
subunit, was disrupted in B. gladioli BCC1622 by insertional 
mutagenesis. LC-MS comparison of extracts from the wild type 
and mutant strains confirmed that gladiostatin (6) production is 
abolished in the mutant (Fig. 4).  
The early stages of gladiostatin (6) biosynthesis appear to 
parallel the assembly of glutarimides in Streptomyces species. 
GdsB and GdsD are proposed to create a GdsC-bound 
malonamyl thioester starter unit, which is elaborated to a 2-(2,6-
dioxopiperidin-4-yl)acetyl thioester intermediate by the first PKS 
module (Fig. 5). Modules 2, 3 and 4 have identical domain 
architectures in all glutarimide PKSs (Fig. 1b). In the 
Streptomyces assembly lines, a single MT domain in module 4 
seems to be responsible for methylating the -carbon of the β-
keto-ACP thioester intermediate generated by the ketosynthase 
(KS) domain in both modules 3 and 4 of the PKSs, installing 
methyl branches at C-8 and C-10 of the resulting glutarimides. In 
contrast, the MT domain in module 4 of the gladiostatin PKS 
appears to methylate only the β-keto thioester intermediate 
attached to the module 3 ACP domain (Fig. 5). Consequently, 
gladiostatin (6) has a methyl branch at C-8, but not C-10. 
Additional studies are needed to understand how PKSs with 
seemingly identical architectures are able to produce the distinct 
C-methylation patterns observed in gladiostatin (6) and the 
Streptomyces glutarimides.  
The domain architecture of modules 5-9 of the gladiostatin 
PKS diverges significantly from the corresponding modules in the 
Streptomyces glutarimide assembly lines. Indeed the C-terminus 
of module 4 appears to be a branch point in all glutarimide-
producing PKSs (Fig. 1b), and could be a recombination hotspot. 
Based on comparisons between the domain architecture and the 
predicted biosynthetic intermediates, module 5 of the gladiostatin 
PKS appears to lack both a ketoreductase (KR) domain (which is  
Fig. 4. Insertional inactivation of gdsE abolishes gladiostatin production 
in B. gladioli BCC1622. Extracted ion chromatograms at m/z 506.27 ± 0.02 
(corresponding to [M+H]+ for gladiostatin) from UHPLC-ESI-Q-TOF-MS analysis 
of ethyl actetate extracts of B. gladioli BCC1622 (top) and the gdsE mutant 
(bottom). 
required for installation of the β-hydroxy group) and an enoyl 
reductase (ER) domain (required to saturate the double bond 
introduced by the dehydratase (DH) domain). Similarly, module 6 
lacks a DH domain and modules 6, 7 and 8 lack ER domains, 
suggesting a high degree of non-linear programming in the 
gladiostatin PKS, which is a common feature of glutarimide 
assembly lines (Fig. 1).[39]
While it is unclear which domains are responsible for the 
keto reduction and dehydration reactions in modules 5 and 6, 
respectively, in silico analysis of the gladiostatin BGC identified 
two genes encoding putative reductases that could function as 
trans-acting ERs in modules 5-8. The gdsB gene encodes a tri-
domain protein with acyl hydrolase (AH) and AT domains fused to 
a flavin-dependent ER domain and gdsH encodes an NAD(P)H-
dependent oxidoreductase. We therefore propose that one, or 
both, of these reductases catalyse enoyl reduction in modules 5, 
6, 7 and 8 of the PKS. A recently reported co-evolutionary 
categorisation of trans-AT PKS ACP domains supports this 
hypothesis, indicating that the module 6, 7 and 8 ACP domains in 
the gladiostatin PKS clade with ACP domains in modules with a 
similar architecture from other assembly lines (i.e. KS-DH-KR-
ACP and a trans-acting ER).[40] Moreover, the TransATor software 
predicts that the KS domains in modules 7, 8 and 9 are selective 
for an α,β-saturated thioester intermediate.[41] However, this 
software also predicts that the module 6 KS domain prefers a α,β-
unsaturated thioester, highlighting potential limitations of such 
predictive bioinformatics analyses (Fig. 5, S18, S19; Table S4 
and S7). 
The most striking difference between the gladiostatin PKS 
and the other glutarimide assembly lines is the mechanism for 
polyketide chain release. All of the Streptomyces glutarimide 
PKSs are proposed to use TE domains that catalyse hydrolysis or 
macrolactonisation. In contrast, the gladiostatin PKS appears to 
employ a PBS domain to catalyse condensation of the -
ketothioester attached to the last module of the PKS with DHAP. 
The resulting phosphorylated butenolide is proposed to undergo 
rearrangement and dephosphorylation to afford a 2-acyl-4- 
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Fig. 5. Proposed pathway for gladiostatin biosynthesis. Domain and module organization of the gladiostatin trans-AT PKS showing the proposed structure of 
each ACP-bound thioester intermediate. KS domains have been numbered sequentially, and the TransATor 42 predictions for their acyl-ACP substrates are shown 
in the dashed box. The A / B subscripts denote the predicted stereospecificity of KR domains. The trans-acting ER domain (gold) of GdsB is predicted to reduce 
enoyl thioesters attached to the ACP domains in modules 5, 6, 7 and 8. Domain abbreviations are as defined in Figure 1. The putative functions of the proteins 
encoded by the gladiostatin biosynthetic gene cluster are listed in Supplementary Table 3. The stereochemistry of C-5 and C-8  is hypothesised to be the same as  
the corresponding stereocentres in lactimidomycin. Comparative seqeunce analysis of the module 2 KR domain predicts that it produces an R-configured alcohol 
(Table S5), consistent with this hypothesis.     
hydroxy-3-methylbutenolide (Fig. 5). This hypothesis is 
consistent with the observed increase in gladiostation production 
levels when glucose is used as the carbon source, because 
DHAP is an intermediate in glycolysis. To our knowledge, there is 
no precedent for PKS chain release by a PBS domain. However, 
PBSs are known to catalyse the condensation of DHAP with a 
range of β-ketothioesters in the biosynthesis of several distinct 
classes of Streptomyces signalling molecule (Fig. 1d). These 
include the SRBs and the SABs, which contain a similar 
butenolide moiety to gladiostatin (6). In addition to the PBS 
(SabA), a phosphatase (SabP) and a ketoreductase (SabD) are 
known to be required for SAB biosynthesis, but the mechanism 
for elaboration of the phosphorylated butenolide produced by 
SabA to the 2-akyl-4-hydroxy-3-methylbutenolide remains to be 
elucidated. The gdsA and gdsG genes in the gladiostatin BGC 
encode putative phosphatases that could play a similar role to 
SabP in the biosynthesis of the SABs (Table S3).  
In vitro reconstitution of chain release from the gladiostatin 
PKS 
To validate the proposed role of the PBS domain in 
gladiostatin (6) biosynthesis, we investigated its catalytic activity 
using simplified mimics of the fully assembled polyketide chain. A 
synthetic gene encoding the C-terminal ACP and PBS domains of 
GdsF was used to overproduce the ACP-PBS di-domain in E. coli
as an N-terminal His8-fusion, which was purified to homogeneity 
using immobilised metal-ion affinity chromatography. The identity 
of the purified protein was confirmed by ESI-Q-TOF-MS analysis 
(Fig. S20).  
The ability of the PBS domain to offload a 3-ketothioester 
from the PKS was examined by loading a 3-ketobutyryl mimic of 
the fully assembled polyketide chain onto the apo-ACP domain 
using the promiscuous phosphopantetheinyl transferase Sfp (Fig. 
S20). The mass of the protein decreased by 86 Da when DHAP 
was added (Fig. S21), consistent with cleavage of the 3-
ketobutyryl group from the ACP domain. 
Incubation of the apo-ACP-PBS di-domain with the N-
acetylcystetamine (NAC) thioester of 3-ketooctanoate and DHAP, 
followed by treatment with shrimp alkaline phosphatase yielded a 
product, absent from the negative control, that gave rise to ions 
with m/z = 213.11 and m/z = 235.09 (corresponding to the [M+H]+
and [M+Na]+, respectively, of the 2-acyl-3-hydroxymethyl 
butenolide (8)) in UHPLC-ESI-Q-TOF-MS analyses (Fig. 6). A 
synthetic standard of 8 had the same retention time and MS/MS 
fragmentation pattern as the product of the enzymatic reaction 
(Fig. 6).  
Conclusion 
The discovery of gladiostatin (6) as the product of a cryptic trans-
AT PKS assembly line in B. gladioli BCC0238 and BCC1622 
further expands the already rich specialised metabolic repertoire 
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of these and related CF isolates.[8,9,11] As the first glutarimide 
antibiotic to be isolated from a Gram-negative bacterium, 
gladiostatin differs significantly from other members of this family, 
all of which are produced by Streptomyces species. While some 
of these structural differences (such as the fully saturated C-11 to 
C-18 chain and the 2-acyl-4-hydroxy-3-methlybutenolide) are 
reflected by alterations in PKS architecture, others (e.g. the lack 
of a C-10 methyl group) are not. The discovery of gladiostatin thus 
offers a golden opportunity to develop a better understanding of 
the role played by horizontal gene transfer in trans-AT PKS 
evolution, which could facilitate biosynthetic engineering 
approaches to polyketide structural diversification.      
Fig. 6. In vitro reconstitution of chain release by the PBS domain. a) 
Condensation of DHAP and the NAC thioester of 3-ketooctanoate by the purified 
recombinant GdsF ACP-PBS di-domain and dephosphorylation of the resulting  
phosphorylated butenolide (7) using shrimp alkaline phosphatase.b) Extracted-
ion chromatograms at m/z = 235.0925 (corresponding to [M+Na]+ for butenolide 
8) from UHPLC-ESI-Q-TOF-MS comparisons of the enzymatic reaction 
cascade and a synthetic standard of 8. The ACP-PBS di-domain was omitted 
from the control reaction. c) Comparison of MS/MS spectra for the synthetic 
standard of butenolide 8 ([M+H]+= 213.11) and the product of the enzymatic 
reaction cascade. 
In vitro characterisation of the AfsA-like PBS domain appended to 
the C-terminus of the gladiostatin PKS shows that it releases 3-
keto thioesters from the upstream ACP domain by condensing 
them with DHAP. This constitutes a new mechanism for 
polyketide chain release, which could prove to be a valuable 
addition to the synthetic biology toolbox. The phosphorylated 
butenolide product of the PBS domain is analogous to the 
intermediate in A-factor biosynthesis produced by AfsA. The 
same kind of intermediate has been shown to be formed by MmfL 
(another AfsA homologue) in the biosynthesis of the 
methylenomycin furans.[42] Thus, it appears that phosphorylated 
2-acyl-3-hydroxymethylbutenolide intermediates are involved in 
the biosynthesis of structurally diverse natural products, including 
GBLs, AHFCAs, AHMB and gladiostatin. However, with the 
exception of GBLs, further work is needed to understand the 
mechanisms by which these intermediates get elaborated into the 
final metabolic products. 
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A new head on old shoulders. Genome mining enabled the discovery of gladiostatin, a novel glutarimide antibiotic from cystic fibrosis-
associated Burkholderia gladioli. Gladiostatin contains an unusual 2-acyl-3-hydroxy-4-methylbutenolide, and exhibits promising activity 
against human cancer cells. The polyketide synthase responsible for its biosynthesis employs a novel mechanism for chain release, 
resulting in formation of a phosphorylated butenolide intermediate.
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